TriSalus Life Sciences, Inc.

NasdaqGM:TLSI Stock Report

Market Cap: US$170.2m

TriSalus Life Sciences Management

Management criteria checks 1/4

TriSalus Life Sciences' CEO is Mary Szela, appointed in Jan 2018, has a tenure of 7.08 years. total yearly compensation is $2.69M, comprised of 19.2% salary and 80.8% bonuses, including company stock and options. directly owns 0.96% of the company’s shares, worth $1.63M. The average tenure of the management team and the board of directors is 1.4 years and 3.2 years respectively.

Key information

Mary Szela

Chief executive officer

US$2.7m

Total compensation

CEO salary percentage19.2%
CEO tenure7.1yrs
CEO ownership1.0%
Management average tenure1.4yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

TriSalus Life Sciences: Falling Despite Moving Forward Into The Market

Jun 25

CEO Compensation Analysis

How has Mary Szela's remuneration changed compared to TriSalus Life Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$57m

Mar 31 2024n/an/a

-US$68m

Dec 31 2023US$3mUS$518k

-US$63m

Sep 30 2023n/an/a

-US$53m

Jun 30 2023n/an/a

-US$59m

Mar 31 2023n/an/a

-US$51m

Dec 31 2022US$861kUS$464k

-US$50m

Compensation vs Market: Mary's total compensation ($USD2.69M) is above average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Mary's compensation has increased whilst the company is unprofitable.

CEO

Mary Szela (60 yo)

7.1yrs

Tenure

US$2,692,830

Compensation

Ms. Mary T. Szela, M.B.A. B.S.N. is Director of LARONDE, Inc. from February 2024. Ms. Szela served as an Independent Director at Prometheus Biosciences, Inc. since February 17, 2021 until June 16, 2023. Ms...

Leadership Team

NamePositionTenureCompensationOwnership
Mary Szela
CEO, President & Director7.1yrsUS$2.69m0.96%
$ 1.6m
Sean Murphy
Chief Manufacturingno dataUS$1.39m1.85%
$ 3.1m
James Young
Chief Financial Officerless than a yearno data0.11%
$ 185.4k
Lori Santamaria
Vice President of Operationsno datano datano data
Jennifer Stevens
Chief Regulatory Officer3.9yrsUS$652.03k0.052%
$ 89.1k
Richard Marshak
Chief Commercial Officerless than a yearno data0.034%
$ 58.2k
Jodi Devlin
Chief of Clinical Strategy & Operations1.4yrsno datano data
Bryan Cox
Chief of Researchno datano data0.22%
$ 382.4k

1.4yrs

Average Tenure

62yo

Average Age

Experienced Management: TLSI's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Mary Szela
CEO, President & Director7.1yrsUS$2.69m0.96%
$ 1.6m
Sean Murphy
Chief Manufacturing3.3yrsUS$1.39m1.85%
$ 3.1m
Kerry Hicks
Independent Director1.5yrsUS$263.70k1.69%
$ 2.9m
Mats Wahlstrom
Independent Chairman8.3yrsUS$323.28k4.25%
$ 7.2m
Christopher Crane
Member of Scientific Advisory Boardno datano datano data
Vincent Picozzi
Member of Scientific Advisory Boardno datano datano data
Divya Sridhar
Member of Scientific Advisory Board3yrsno datano data
Jordan Tasse
Member of Scientific Advisory Board3yrsno datano data
Richard Carvajal
Member of Scientific Advisory Boardno datano datano data
Marlana Orloff
Member of Scientific Advisory Boardno datano datano data
Sapna Patel
Member of Scientific Advisory Boardno datano datano data
Ripal Gandhi
Member of Scientific Advisory Boardno datano datano data

3.2yrs

Average Tenure

67yo

Average Age

Experienced Board: TLSI's board of directors are considered experienced (3.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/11 08:46
End of Day Share Price 2025/02/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TriSalus Life Sciences, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William PlovanicCanaccord Genuity
Ross OsbornCantor Fitzgerald & Co.
Justin WalshJonesTrading Institutional Services, LLC